Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
CIDARA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 0.7809 USD | +10.08% | +9.99% | +3.25% | |
Financials (USD)
| Sales 2023 * | 57.85 M | Sales 2024 * | 21.07 M | Capitalization | 70.62 M |
|---|---|---|---|---|---|
| Net income 2023 * | -27.00 M | Net income 2024 * | -56.00 M | EV / Sales 2023 * | 1,22x |
| Net cash position 2023 * | - | Net cash position 2024 * | - | EV / Sales 2024 * | 3,35x |
| P/E ratio 2023 * | -2,55x | P/E ratio 2024 * | -1,35x | Employees | 73 |
| Yield 2023 * | - | Yield 2024 * | - | Free-Float | 92.68% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | +10.08% | ||
| 1 week | +9.99% | ||
| Current month | +10.08% | ||
| 1 month | -2.81% | ||
| 3 months | -1.15% | ||
| 6 months | -40.84% | ||
| Current year | +3.25% |
1 week
0.68
0.79
1 month
0.590.91
Current year
0.592.10
1 year
0.462.10
3 years
0.403.15
5 years
0.404.45
10 years
0.4019.13
| Managers | Title | Age | Since |
|---|---|---|---|
Jeffrey Stein
CEO | Chief Executive Officer | 68 | 2013 |
Preetam Shah
DFI | Director of Finance/CFO | 50 | 2021 |
Les Tari
CTO | Chief Tech/Sci/R&D Officer | 56 | 2012 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Daniel Burgess
CHM | Chairman | 61 | 2014 |
| Director/Board Member | 68 | 2014 | |
Jeffrey Stein
CEO | Chief Executive Officer | 68 | 2013 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.33% | 5 M€ | -13.59% | ||
| 0.02% | 678 M€ | -2.75% | ||
| 0.00% | 13,379 M€ | +15.26% | ||
| 0.00% | 30 M€ | +12.70% | - | |
| 0.00% | 4,253 M€ | +18.88% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-12-01 | 0.7809 | +10.08% | 531,867 |
| 23-11-30 | 0.7094 | +2.66% | 295,846 |
| 23-11-29 | 0.6910 | +1.32% | 255,396 |
| 23-11-28 | 0.6820 | -3.00% | 386,448 |
| 23-11-27 | 0.7031 | -0.97% | 283,997 |
Delayed Quote Nasdaq, December 01, 2023 at 04:00 pm EST
More quotes
Cidara Therapeutics, Inc. is a biotechnology company. The Company is focused on the discovery, development and commercialization of therapeutics designed for patients facing serious diseases. The Company's lead product candidate is rezafungin acetate, an intravenous formulation of an echinocandin. Rezafungin is being developed as a once-weekly, high-exposure therapy for the treatment and prevention of serious invasive fungal infections. The Company's primary focus is using its Cloudbreak platform to develop a potential new class of drugs called drug-Fc conjugates (DFCs), for the prevention and treatment of serious diseases. This technology couples? potent inhibitors to a human antibody fragment to create long-acting DFCs designed to inhibit multiple disease targets. Its advanced DFC program is CD388, a long-acting antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase I and Phase IIa clinical trials.
Calendar
2024-02-27
- Q4 2023 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.7809USD
Average target price
4.667USD
Spread / Average Target
+497.60%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +3.25% | 71 M $ | |
| +21.60% | 90 488 M $ | |
| +12.94% | 86 658 M $ | |
| +2.47% | 34 551 M $ | |
| +19.81% | 26 777 M $ | |
| -33.83% | 23 629 M $ | |
| -26.62% | 20 547 M $ | |
| -14.75% | 19 529 M $ | |
| -1.94% | 11 507 M $ | |
| +20.17% | 10 906 M $ |
